- Previous Close
80,300.00 - Open
81,500.00 - Bid 86,200.00 x --
- Ask 86,300.00 x --
- Day's Range
81,500.00 - 86,100.00 - 52 Week Range
28,350.00 - 125,900.00 - Volume
270,778 - Avg. Volume
280,941 - Market Cap (intraday)
1.546T - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
160,000.00
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
voronoi.ioRecent News: 310210.KQ
View MorePerformance Overview: 310210.KQ
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 310210.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 310210.KQ
View MoreValuation Measures
Market Cap
1.55T
Enterprise Value
1.48T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
20.74
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.70%
Return on Equity (ttm)
-78.61%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.07B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
61.27B
Total Debt/Equity (mrq)
18.58%
Levered Free Cash Flow (ttm)
-19.43B